Transcatheter mitral valve implantation (TMVI) with the novel Tendyne transcatheter heart valve showed a high success rate, with significant reduction in mitral regurgitation (MR) and symptoms improvement at 30 days after the procedure, in patients not eligible for transcatheter edge-to-edge repair (TEER) of the mitral valve, according to late-breaking trial results presented Wednesday at Transcatheter Valve Therapies (TVT) 2021.